-
![vaccine, disease prevention-GettyImages-1155084813]( "Dual Membrane Preconditioning Can Improve Concentration, Cut HCPs")
Dual Membrane Preconditioning Can Improve Concentration, Cut HCPsResearch from Penn State, the FDA, and Takeda shows how combination filtration and purification steps improve output and reduce impurities.
-
![Cell Culture Media Filtration]( "Cell Culture Media Filtration: Evaluating Cell Culture Performance")
Cell Culture Media Filtration: Evaluating Cell Culture PerformanceCell culture performance remained consistent across PES and PVDF filters, even under worst-case filtration conditions. Discover a practical framework for evaluating membrane impact on CHO cell growth.
-
![Scientist with tablet in laboratory-GettyImages-1470739489]( "New Guide Aims To Build Robust Framework For Digital Validation Tools")
New Guide Aims To Build Robust Framework For Digital Validation ToolsThe ISPE's new guide addresses software for managing digital assets related to qualification, verification, validation, and compliance assurance.
-
![Eurasia and africa digital display-GettyImages-1368021598]( "Pfizer's Accord For A Healthier World Program Challenges Stability Study Norms")
Pfizer's Accord For A Healthier World Program Challenges Stability Study NormsThe company developed a novel approach to address the historic lack of stability testing for underserved parts of the world, near the equator.
-
![growing chart of medical pills-GettyImages-2159767302]( "The 9 Fastest-Growing Outsourcing Segments")
The 9 Fastest-Growing Outsourcing SegmentsCapacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
-
![Modern High-Tech Laboratory, Genetics and Pharmaceutical Studies and Researches-GettyImages-1158419934]( "Takeda Reimagines Biopharma Quality For The Digital Age")
Takeda Reimagines Biopharma Quality For The Digital AgeArtificial intelligence, even in its current form, is especially good at synthesizing large data sets. Here's how one company makes the most of it.
-
![Lipid Nanoparticles GettyImages-1437855772]( "How Lipid Nanoparticles Enable Next-Gen Delivery")
How Lipid Nanoparticles Enable Next-Gen DeliveryCell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
![GettyImages-2179880251-digital-validation-hands-blue]( "Streamline Process Development, Digitize Data, And Maximize Your Investments")
Streamline Process Development, Digitize Data, And Maximize Your InvestmentsDiscover how AI, digital twins, and automation are transforming biomanufacturing by cutting costs, improving quality, and accelerating timelines for smarter, more efficient production.
-
![big pharma, private equity funds-GettyImages-2208792176]( "100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing")
100% U.S. Drug Tariffs: Implications For Pharma And OutsourcingResearch Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.
-
![Risk meter-GettyImages-1585559879]( "Risk-Based Analytical Method Selection In Cleaning Validation Using ASTM International Standards")
Risk-Based Analytical Method Selection In Cleaning Validation Using ASTM International StandardsThis in-depth article describes risk in cleaning and provides a science- and risk-based framework for selecting analytical methods using ASTM International standards.
-
![Vaccine vial does-GettyImages-1199794733]( "What Can The Tech Sector's 'Minimally Viable' Concept Teach Biopharma?")
What Can The Tech Sector's 'Minimally Viable' Concept Teach Biopharma?Deciding what is good enough to get started can support the mindset of building something without sacrificing quality, functionality, or safety.
-
![Scientist Using Bioreactor GettyImages-532549174]( "Fermentation Of Live Biotherapeutic Products In cGMP Environments")
Fermentation Of Live Biotherapeutic Products In cGMP EnvironmentsWe follow the journey from master cell bank to large-scale anaerobic fermentation, highlighting the unique needs for working with oxygen-sensitive, strictly anaerobic therapeutic microbes in a cGMP setting.
-
![Abstract arrow direction-GettyImages-1427276149]( "What If We Had Just One Developability Parameter?")
What If We Had Just One Developability Parameter?Research suggests years-long stability studies that gobble up material can be reduced to a single day using milligram quantities.
-
![Artificial intelligence, AI, digital-GettyImages-2151606282]( "Trust But Verify: Validating AI In Pharma's GxP World")
Trust But Verify: Validating AI In Pharma's GxP WorldHere are practical tips to build validated, transparent, and auditable AI systems that align with GxP principles, paving the way for smarter and more resilient manufacturing processes.
-
![Pellicon]( "Achieve Higher Targeted Concentrations")
Achieve Higher Targeted ConcentrationsSingle-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
ABOUT BIOSIMILAR MANUFACTURING
Biosimilars are considered to be low-cost substitutions for pricy, large-molecule biologics. However, biosimilars must meet the same quality, safety, and efficacy as their reference biologic. Manufacturing biosimilars requires a more complicated procedure than that of manufacturing small molecule generics. Companies manufacturing biosimilars are focused on creating a chemical structure that is as close as possible to that of the reference product. Failure rates and operational costs pose a challenge for those companies involved in manufacturing biosimilars compared to those manufacturing small molecule generics.
Small molecule generics are created using the same active pharmaceutical ingredient (API) and, therefore, are chemically identical to that of the originator medicine. The manufacturing process for small molecules comprises only one-fifth of the total in-process tests required to meet Good Manufacturing Practice compared to that of biologic medicines (50 vs. 250 in-process tests). In fact, the manufacturing process for a large molecule is so complex, it cannot be duplicated by two different manufacturers, as the cells used in biologic medicines are unique to the company manufacturing each biologic.
Manufacturing a biologic consists of genetically modifying a cell, which becomes the basis for a cell line used for the production of the necessary protein for the biologic medicine. The protein is then separated from the cells and purified. Biosimilars are created from small alterations to the manufacturing process which creates a molecule that is not identical but closely resembles the reference product. While the differences in the biosimilar molecule might be slight, these changes in the manufacturing process of a biosimilar can affect the efficacy and safety of a biosimilar compared to the reference biologic. Over the past decade, the manufacturing process for proteins has become more standardized and the required technology has become increasingly accessible, leading to reductions in biosimilars production costs. As a result, a greater number of companies have begun manufacturing biosimilars, while reference brand manufacturers are setting their sights on bolstering pipelines and manufacturing biobetters to maintain market share for their soon-to-be-off-patent reference products.
BIOSIMILAR DEVELOPMENT NEWS
- AAM Requests Federal Injunction To Block Connecticut's Unconstitutional Drug Price Law
- Biocon Biologics Receives Health Canada Approval For Yesintek™ And Yesintek™ I.V. (ustekinumab), A Biosimilar To Stelara®
- Alvotech Announces Changes In Global Business Development And Commercial Operations Team
- Formycon's FYB201/Ranivisio Sets Innovative Standard As Europe's First Ranibizumab Biosimilar Available In Pre-Filled Syringe
- Polpharma Biologics Announces Commercial Launch Of Europe's First Pre-Filled Syringe Presentation Of A Ranibizumab Biosimilar